Cardiac Troponin I Concentration May Predict Mortality

THURSDAY, Aug. 10, 2023 (HealthDay News) -- Cardiac troponin I (cTnI) concentration is associated with medium-term mortality in an unselected hospital population, according to a study published online Aug. 7 in Heart.
Jonathan Hinton, from the University of Southampton in the United Kingdom, and colleagues conducted a prospective observational study including 20,000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital and in whom a high-sensitivity cTnI assay was measured.
Overall, 91.4 percent of the patients did not have a clinical indication for cTnI testing. The researchers found that 14.1 percent of patients died at a median of 809 days. If the cTnI concentration was above the upper limit of normal, mortality was significantly higher (45.3 versus 12.3 percent). In a multivariable analysis, log10 cTnI concentration was independently associated with mortality (hazard ratio, 1.76). The relationship persisted in a landmark analysis, excluding deaths within 30 days.
"These findings suggest that a snapshot cTn in a hospital population may represent a biomarker of overall medium-term mortality," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Related Posts
Patient Preferences Examined for CRC Screening Modalities
WEDNESDAY, Sept. 21, 2022 (HealthDay News) -- Unscreened adults aged 40 years...
Gene Changes Made This Season’s Bird Flu More Severe
FRIDAY, June 2, 2023 (HealthDay News) -- Genetic mutations caused this latest...
Los veteranos podrían tener un riesgo más bajo de ETC que los exdeportistas
VIERNES, 10 de junio de 2022 (HealthDay News) -- Una afección degenerativa del...